Status:
COMPLETED
Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Lead Sponsor:
Ziauddin University
Collaborating Sponsors:
Jinnah Sindh Medical University
Conditions:
Triple Negative Breast Cancer
Eligibility:
FEMALE
24-45 years
Brief Summary
The goal of this observational study is to learn about the effects of neoadjuvant chemotherapy (NACT) anthracycline-containing, taxane- (Intervention A +T) and anthracycline/taxane /carboplatin (Inter...
Detailed Description
Stromal tumor-infiltrating lymphocytes (TILs) are currently being considered as a prognostic factor in triple-negative breast cancer (TNBC) and their association with the tumor immune microenvironment...
Eligibility Criteria
Inclusion
- Female (aged 24-45 years) TNBC patients
- Diagnosed TNBC Patients with immunohistochemistry (IHC) negative test for estrogen receptor (ER), progesterone receptor (PR), and HER-2
- Patients with and without metastases
Exclusion
- Patients who had a history of other malignant tumors
- Patients who did not complete NAC.
Key Trial Info
Start Date :
January 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT06965361
Start Date
January 2 2021
End Date
July 31 2022
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shamim
Karachi, Sindh, Pakistan, 75270